Maxim downgraded scPharmaceuticals (SCPH) to Hold from Buy after the company agreed to be acquired by MannKind (MNKD) for $5.35 per share in cash at closing plus one non-tradable contingent value right per share to receive certain milestone payments of up to an aggregate of $1.00 per CVR in cash, for total consideration of up to $6.35 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH:
- scPharmaceuticals Announces Merger with MannKind Corporation
- MannKind to acquire scPharmaceuticals for up to $6.35 per share in cash
- scPharmaceuticals Extends SmartDose Supply Agreement
- scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111
- scPharmaceuticals Q2 2025 Earnings Call Highlights Growth